Email this article IMMUNOHISTOCHEMICAL AND MOLECULAR GENETIC PROGNOSTIC FACTORS FOR EARLY-STAGE INVASIVE BLADDER CANCER
- Authors: Chernyshev I.V.1, Efremov G.D.1, Tertychnyi A.S.2, Perepechin D.V.1
-
Affiliations:
- Research Institute of Urology, Moscow
- I.M. Sechenov First Moscow Medical University
- Issue: Vol 7, No 3 (2011)
- Pages: 20-24
- Section: LECTURE
- Published: 30.09.2011
- URL: https://oncourology.abvpress.ru/oncur/article/view/286
- DOI: https://doi.org/10.17650/1726-9776-2011-7-3-20-24
- ID: 286
Cite item
Full Text
Abstract
Bladder cancer (BC) is one of the most common malignancies. More than 90 % of the notified cases are morphologically diagnosed as transitional cell carcinoma; moreover, over 70 % of them are the early stages (Ta, Tis, and T1) of the disease. Patients with diagnosed T1 tumor are deemed to be the most difficult group of patients with early-stage BC. Despite the generally good prognosis of the course of this stage of BC after performed therapy, the tumor recurs in most patients and progresses to a more disseminated stage in 15–20 %. In this connection, there is a continuous search for the prognostic markers associated with the poor prognosis of the disease. A number of morphological, immunohistochemical, and molecular signs that, according to the investigators’ data, correlate with the risk for BC recurrence and progression have been identified. Nonetheless, a diagnostic testing algorithm that permits the prediction of the course of the disease from primary histological data remains to be elaborated. There should be further investigations that enable one to develop an informative panel of diagnostic and prognostic markers that allow a pathologist to correctly define the stage and prognosis of the disease and a clinician to choose an optimal treatment policy for each patient.
About the authors
I. V. Chernyshev
Research Institute of Urology, Moscow
Email: efremov.gen@yandex.ru
Russian Federation
G. D. Efremov
Research Institute of Urology, Moscow
Author for correspondence.
Email: efremov.gen@yandex.ru
Russian Federation
A. S. Tertychnyi
I.M. Sechenov First Moscow Medical University
Email: efremov.gen@yandex.ru
Russian Federation
D. V. Perepechin
Research Institute of Urology, Moscow
Email: efremov.gen@yandex.ru
Russian Federation
References
Supplementary files
